Research
Malaria vaccine shows 87% efficacy in clinical trial
The Brief
- A genetically attenuated whole-parasite malaria vaccine, PfSPZ-LARC2, showed 87% efficacy in preventing infection in a recent phase 1 trial.
- The figure is reported by Medical Xpress in a story dated 2026-11-20.
- The source does not give trial size, population, or follow-up details.
Why it matters
A reported 87% efficacy against infection in a phase 1 trial is an early signal for a whole-parasite malaria vaccine approach, but phase 1 results alone do not establish protection in wider populations.
Who’s affected
- malaria researchers and vaccinologists
- global health practitioners following malaria vaccine development
- #malaria
- #vaccine
- #clinical-trial
- #infectious-disease
- #whole-parasite-vaccine
The novel, genetically attenuated whole-parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.